acute mountain sickness
Conditions
Interventions
Oral Trimetazidine:Oral Trimetazidine 20mg, Tid
Placebo:Oral placebo 20mg, Tid
Sponsors
Institute of Cardiovascular Diseases of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, China
Eligibility
Sex/Gender
All
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 35 years; 2. People acutely ascending to high altitude. The gender ratio depends on actual situation; 3. there is no history of plateau for a long time exposure; 4. Before assessment, all subjects must be voluntary and sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. The recent history of taking acute mountain sickness prevention drugs; 2. Engaged in specialized sports training; 3. Subjects with bad comp1iance; 4. The recent history of upper respiratory tract infection; 5. Subjects cannot take the drugs in our trial because of allergic history or other reasons; 6. Subjects with psychological or neurological disorderand other conditions which are not appropriate for our trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PWC170;blood lactic acid;Lake Louise Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart Rate;blood pressure;oxygen saturation;ECG;UCG;sleep quality;vascular endothelial function;SCL-90;6 minutes walk test;sit-up;push-up;4*10m shuttle run;MDA;VWF;ADMA; | — |
Countries
China
Contacts
Public ContactHuang Lan
Outcome results
None listed